Predicting Recurrence of C. difficile Colitis Using Bacterial Virulence Factors: Binary Toxin Is the Key

Journal of Gastrointestinal Surgery

Volumn 17, Issue 1, 2013, Pages 118-125

  Stewart, David B ^a   Berg, Arthur ^a   Hegarty, John ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Binary toxin; Clostridium difficile; Recurrence; Virulence

Indexed keywords

EID: 84871951172     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11605-012-2056-6     Document Type: Article

References (32)

1. Bartlett JG, Perl TM. The new Clostridium difficile-what does it mean? N Engl J Med 2008; 353(23): 2503-05.
2. Dallal RM, Harbrecht BG, Boujoukas AJ, et al. Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann Surg 2002; 235(3): 363-372.
3. Pepin J, Valiquette L, Alary ME, et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 2004; 171(5): 466-472.
4. Warny M, Pepin J, Fang A, et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005; 366: 1079-84.
5. McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005; 353: 2433-41.
6. McFarland LV, Surawicz CM, Rubin M, et al. Recurrent Clostridium difficile disease: epidemiology and clinical characteristics. Infect Control Hosp Epidemiol 1999; 20: 43-50.
7. McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 2002; 97(7): 1699-75.
8. McFarland LV, Surawicz CM, Rubin M, Fekety R, et al. Recurrent Clostridium difficile disease: epidemiology and clinical characteristics. Infect Control Hosp Epidemiol 1999; 43-50.
9. Jabbar U, Leischner J, Kasper D, Gerber R, et al. Effectiveness of alcohol-based hand rubs for removal of Clostridium difficile spores from hands. Infect Control Hosp Epidemol 2010; 31(6): 565-70.
10. Stevens V, Dumyati G, Fine LS, Fisher SG, van Wijngaarden E. Cumulative antibiotic exposures over time and the risk of Clostridium difficile infection. Clin Infect Dis 2011; 53(1): 42-8.
11. FDA U. S. Food and Drug Administration. Accessed on 4/2/2012; http://www. fda. gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm290838. htm.
12. Rupnik M, Avesani V, Janc M, von Eichel-Streiber C, Delmée M. A novel toxinotyping scheme and correlation of toxinotypes with serogroups of Clostridium difficile isolates. J Clin Microbiol 1998; 36(8): 2240-7.
13. Stubbs SL, Brazier JS, O'Neill GL, Duerden BI. PCR targeted to the 16S-23S rRNA gene intergenic spacer region of Clostridium difficile and construction of a library consisting of 116 different PCR ribotypes. J Clin Microbiol 1999; 37: 461-63.
14. Spigaglia P, Mastrantonio P. Molecular analysis of the pathogenicity locus and polymorphism in the putative negative regulator of toxin production (TcdC) among Clostridium difficile clinical isolates. J Clin Microbiol 2002; 40(9): 3470-5.
15. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-83.
16. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010; 31: 431-55.
17. Popoff MR, Rubin E, Gill DM, Boquet P. Actin-specific ADP-ribosyltransferase produced by a Clostridium difficile strain. Infect Immun 1988; 56: 2299-306.
18. Thelestram M, Chaves-Olarte E. Cytotoxic effects of the Clostridium difficile toxins. Cur Top Microbiol Immunol 2000; 250: 85-96.
19. Rupnik M, Grabnar M, Geric B. Binary toxin producing Clostridium difficile strains. Anaerobe 2003; 9: 289-294.
20. Barth H, Aktories K, Popoff MR, Stiles BG, et al. Binary bacterial toxins: biochemistry, biology, and applications of common Clostridium and Bacillus mechanism of ADP ribosylating toxins. FEBS J 2006; 273: 4579-4593.
21. Sundriyal A, Roberts AK, Ling R, McGlashan J, et al. Expression, purification and cell cytotoxicity of actin-modifying binary toxin from Clostridium difficile. Protein Expr Purif 2010; 74: 42-48.
22. Vandekerckhove J, Schering B, Barmann M, et al. Clostridium perfringens iota toxin ADP ribosylates skeletal muscle actin in Arg-177. FEBS Lett 1987(225): 48-52.
23. Reuner KH, Presek P, Boschek CB, et al. Botulinum C2 toxin ADP-ribosylates actin and disorganizes the microfilament network in intact cells. Eur J Cell Biol 1987; 43: 134-140.
24. Davies AH, Roberts AK, Shone CC, Acharya KR. Super toxins from a super bug: structure and function of Clostridium difficile toxins. Biochem KJ 2011; 436: 517-526.
25. Geric B, Johnson S, Gerding DN, Grabnar M et al. Frequency of binary toxin genes among Clostridium difficile strains that do not produce large clostridial toxins. J Clin Microbiol 2003; 41: 5227-32.
26. Stubbs S, Rupnik M, Gilbert M, Brazier J, et al. Production of actin specific ADP-ribosyltransferase (binary toxin) by strains of Clostridium difficile. FEMS Microbiol Lett 2000; 186: 307-312.
27. Goldenberg AD, French GL. Lack of association of tcdC type and binary toxin status with disease severity and outcome in toxigenic Clostridium difficile. J Infect 2011; 62(5): 355-362.
28. McCarthy DM. Adverse effects of proton pump inhibitor drugs: clues and conclusions. Curr Opin Gastroenterol 2010; 26: 624-631.
29. Naggie S, Miller BA, Zuzak KB, et al. A case-control study of community-associated Clostridium difficile infection: no role for proton pump inhibitors. Am J Med 2011; 124(3): 276. e1-276. e7.
30. Kim YG, Graham DY, Jang BI. Proton pump inhibitor use and recurrent Clostridium difficile-associated disease. J Clin Gastroenterol 2012; 46(5): 397-400.
31. Dial S, Delaney JA, Barkun AN, et al. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 2005; 294: 2989-95.
32. Dupuy B, Govind R, Antunes A, Matamouros S. Clostridium difficile toxin synthesis is negatively regulated by TcdC. J Med Microbiol 2008; 57: 685-689.